All In Biotech

Drug Trial Radar · NCT05937750

A Long-term Follow-up Trial of Patients Previously Treated With Imlifidase Prior to Kidney Transplantation and a Non-comparative Transplanted Patient Group

A Prospective, Post-authorisation Long-term Follow-up Trial of Patients Previously Treated With Imlifidase Prior to Kidney Transplantation, Including a Non-comparative Concurrent Reference Cohort

Last checked: Nov 19, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Jul 3, 2023

Primary completion

Apr 30, 2030

Study completion Apr 30, 2030

Sponsor

Lead sponsor
Hansa Biopharma ABIndustry
Sponsor type
Industry
First posted
Jul 10, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 19 years, up to 76 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A prospective, post-authorisation long-term follow-up trial of patients previously treated with imlifidase prior to kidney transplantation, including a non-comparative concurrent reference cohort.

Conditions

  • Long Term Efficacy and Safety

Interventions

  • Imlifidase administered in the 20-HMedIdeS-19 (PAES) studyDrug

    Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.

  • Best available treatment administered in the 20-HMedIdeS-19 (PAES) studyOther

    Normal transplantation routine Transplantation and pre- and post-transplantation therapies in accordance with the clinic's normal transplantation routine.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Graft failure-free survival (%) up to 5 years after imlifidase enabled transplantation (imlifidase cohort only)Time frame: 5-years after transplantation

Locations

14 sites in 7 countries. Site status is shown where the registry gives one.

  • Medizinische Universitaet Wien

    Vienna, Austria

  • Nephrology Clinic Vídeňská 1958/9

    Prague, Czechia

  • Hôpital Necker - Enfants Malades

    Paris, France

  • Centre Hospitalier Universitaire (CHU) de Rouen - Hôpital de Bois-Guillaume

    Bois-Guillaume, Normandy, France

  • Azienda Ospedaliera di Padova

    Padova, Italy

  • Azienda Ospedaliero - Universitaria di Parma

    Parma, Italy

  • Leiden University Medical Center

    Leiden, Netherlands

  • Erasmus University Medical Center

    Rotterdam, Netherlands

  • Hospital Del Mar, Servicio de Nefrología

    Barcelona, Spain

  • Hospital Universitario del Vall d´Hebron

    Barcelona, Spain

  • Unidad de Trasplante Renal

    Barcelona, Spain

  • Hospital Universitario 12 De Octubre

    Madrid, Spain

  • Uppsala University Hospital

    Uppsala, Sweden

  • Karolinska University Hospital,

    Huddinge, Stockholm County, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.